China-based Innovent Biologics Inc. (HKG: 1801) and Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma, SHE: 002755) have announced a strategic collaboration and licensing agreement focused on ASK’s limertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed for lung cancer treatment. Under the terms of the deal, Innovent will acquire exclusive commercial rights to limertinib in mainland China and will receive a fee based on net sales. ASK will retain its status as the marketing authorization holder and will manage manufacturing and commercial supply, while also standing to gain upfront, regulatory, and sales-based milestone payments from Innovent.
Limertinib is an orally administered, novel third-generation EGFR TKI, with two New Drug Applications (NDAs) filed in China. The first NDA targets adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) whose disease has progressed after prior EGFR TKI therapy. The second NDA is for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.-Fineline Info & Tech
